MedPath

Hyaluronidase (human recombinant)

Generic Name
Hyaluronidase (human recombinant)
Brand Names
Darzalex Faspro, Herceptin Hylecta, Hylenex, Hyqvia 5 G / 50 Ml Kit, Phesgo, Rituxan Hycela, Vyvgart Hytrulo
Drug Type
Biotech
Chemical Formula
-
CAS Number
757971-58-7
Unique Ingredient Identifier
743QUY4VD8
Background

A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication

Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Conditions
Drug Extravasation, Generalized Myasthenia Gravis, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Primary Immune Deficiency Disorders (PIDD), Primary Immunodeficiency, Secondary humoral immunodeficiency, Stage I Breast Cancer
Associated Therapies
Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
Clinical Trials
Related News
biospace.com
·

J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials

J&J announced positive clinical trial data for its multiple myeloma drugs Carvykti and Darzalex Faspro, showing improved outcomes. Carvykti demonstrated a 45% reduction in death risk and 76% OS rate at 30 months, while Darzalex Faspro improved minimal residual disease-negativity by 60.9%.
morningstar.com
·

Cepheus Phase 3 Study Shows Improvement for Patients With Multiple Myeloma

Johnson & Johnson's darzalex faspro treatment showed 60.9% improvement in eliminating cancer cells and 43% reduction in progression or death for newly diagnosed multiple myeloma patients in Cepheus phase 3 trial.
prnewswire.com
·

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep ...

DARZALEX FASPRO® in maintenance therapy significantly increased MRD-negativity rate at 12 months compared to lenalidomide alone, improving 30-month progression-free survival in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.

Related Clinical Trials:

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
finance.yahoo.com
·

Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of ...

FDA approves Johnson & Johnson's Rybrevant in combination with chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations, marking its third approval in 2024.
drugs.com
·

Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

FDA approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplant (ASCT), supported by Phase 3 PERSEUS study data showing significant improvement in progression-free survival (PFS) and deeper responses with D-VRd compared to VRd.
finance.yahoo.com
·

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript

Halozyme Therapeutics reported strong Q4 and full-year 2023 results, with a 26% revenue increase to $829M and a 24% rise in royalty revenue to $448M. The company highlighted growth from its ENHANZE technology and commercial products, projecting 2024 revenue between $915M and $985M. Key achievements include advancements in subcutaneous drug delivery and partnerships, with a focus on expanding its pipeline and leveraging its high-volume auto-injector technology.
finance.yahoo.com
·

15 Worst Performing Biotech Stocks in 2023

The biotech industry, valued at $1.2 trillion, faces challenges post-pandemic with reduced revenues, regulatory pressures, and decreased FDA approvals. Funding has significantly dropped, impacting innovation. In 2023, biotech stocks like Jazz Pharmaceuticals, Incyte Corporation, and Ultragenyx Pharmaceutical are among the worst performers, with significant YTD share price declines.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy